NCT05174013View on ClinicalTrials.gov

Safety, Tolerability, Pharmacokinetics and Target Engagement of GSK3858279 in Healthy Caucasian, Chinese and Japanese Participants

PHASE1CompletedINTERVENTIONAL

Enrollment

33

Participants

Timeline

Start Date

February 14, 2022

Primary Completion Date

February 10, 2023

Study Completion Date

April 17, 2023

Conditions

Pain

Interventions

DRUG

GSK3858279

GSK3858279 will be administered

DRUG

Placebo

Placebo will be administered

Trial Locations (2)

3004

GSK Investigational Site, Melbourne

4006

GSK Investigational Site, Herston Queensland

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY

NCT05174013 - Safety, Tolerability, Pharmacokinetics and Target Engagement of GSK3858279 in Healthy Caucasian, Chinese and Japanese Participants | Biotech Hunter | Biotech Hunter